Other languages Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
0.7045 ^USD	-8.51%		-14.05%	-7.30%

May. 09	Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 22	Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762	Apr. 22
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology	Apr. 16
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	Mar. 21
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research	Mar. 13
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders	Mar. 06
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders	Mar. 06
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas	Nov. 09
Phio Pharmaceuticals Shares Rise After Data Shows Intasyl Compound Enhances Tumor Control	Nov. 03
Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer	Nov. 03
Top Premarket Decliners	23-10-12
Top Midday Gainers	23-10-11
Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894	23-10-11
Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute	23-08-21
Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Phio Pharmaceuticals Completes $4 Million Securities Offering	23-06-02
Phio Pharmaceuticals to Raise $4 Million From Securities Offering; Shares Fall	23-05-31
Sector Update: Health Care Stocks Weaker Late Thursday	23-05-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Other languages

Filters